Pediatric viral skin infections

Clinics in Family Practice

Volumn 5, Issue 3, 2003, Pages 589-607

  Purdon, Michael ^a,b   Ruddy, Ginger ^a  

^a Swedish Family Medicine Residency   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ACICLOVIR; ANTIBIOTIC AGENT; BEHENYL ALCOHOL; BLEOMYCIN; CANTHARIDIN; CIDOFOVIR; CIMETIDINE; DICHLOROACETIC ACID; EMLA; FAMCICLOVIR; FOSCARNET; HYDROCORTISONE; IMIQUIMOD; INTERFERON; IODINE; LACTIC ACID; LEVAMISOLE; LIDOCAINE; LIQUID NITROGEN; PENCICLOVIR; PHENOL; PLACEBO; RHUBARB EXTRACT; SALICYLIC ACID; SQUARIC ACID; TETRACAINE; TRICHLOROACETIC ACID; UNINDEXED DRUG; VALACICLOVIR;

CHILDHOOD DISEASE; CLINICAL TRIAL; COST CONTROL; COXSACKIE VIRUS INFECTION; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ELECTROSURGERY; EXPOSURE; HAND FOOT AND MOUTH DISEASE; HERPES LABIALIS; HUMAN; IMMUNITY; INCIDENCE; MOLLUSCUM CONTAGIOSUM; NAUSEA; NONHUMAN; ONSET AGE; PAIN; PREDICTION; REVIEW; SKIN CARE; SKIN INFLAMMATION; SKIN IRRITATION; STOMATITIS; TREATMENT PLANNING; VERRUCA VULGARIS; VIRAL SKIN DISEASE;

EID: 0348038762     PISSN: 15225720     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-5720(03)00045-X     Document Type: Review

References (90)

1. Goldstein B, Goldstein A. Cutaneous warts. In: Rose BD, editor. UpToDate. Wellesley (MA): UpToDate; 2003.
2. Syrjanen K, Syrjanen S. HPV infections of the skin: papillomavirus infections in human pathology. New York: John Wiley & Sons; 2000.
3. Gibbs S, Harvey I, Sterling JC, et al. Local treatments for cutaneous warts. Cochrane Database Syst Rev. 2001;2:CD001781.
4. Mandell GL, Bennet JE, Dolin R. Principles and practice of infectious diseases. 5th edition. New York: Churchill Livingstone; 2000. p. 1393-4.
5. Kilkenny M, Erlin K, Young R, et al. The prevalence of common skin conditions in Australian school students: common, plane and plantar viral warts. Br J Dermatol 1998; 138:840.
6. Allen AL, Siegfried EC. What's new in human papillomavirus infection. Curr Opin Pediatr 2000;12:365-9.
7. Plasencia JM. Cutaneous warts: diagnosis and treatment. Prim Care 2000;27:423-34.
8. Cotran R. Robbins pathologic basis of disease. 6th edition. Philadelphia: W.B. Saunders; 1999.
9. Pleat J, Sacks L, Rigby H. Cutaneous verrucous carcinoma. Br J Plast Surg 2001;54: 168-70.
10. Garman ME. The cutaneous manifestations of HIV infection. Dermatol Clin 2002;20: 193-208.
11. Iraji F, Kiani A, Shahidi S, Vahabi R. Histopathology of skin lesions with warty appearance in renal allograft recipients. Am J Dermatopathol 2002;24:324-5.
12. Lutzner MA, Blanchet-Bardon C, Orth G. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 1984;83:18S.
13. Majewski S, Malejczyk J, Jablonska S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1990;22:423-7.
14. Young R, Kilkenny MF, Jolley D, et al. Development of diagnostic criteria for warts (verrucae vulgaris). J Cut Med Surg 1997;2:78-82.
15. Young R. Comparison of the use of standardized diagnostic criteria and intuitive clinical diagnosis of common viral waits (Verrucae Vulgaris). Arch Dermatol 1998; 134:1586-9.
16. Massing AM, Estonia WL. Natural history of warts: a two year study. Arch Dermatol 1963;87:306-10.
17. Bigby M, Gibbs S, Harvey I, et al. Non-genital warts. Clin Evid 2002;8:1731-44.
18. Melore GG. Chemical treatment of verrucae. Optom Clin 1992;2:135-42.
19. Zabouski EJ, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998;39:741-5.
20. Landsman MJ, Mancuso JE, Abramow SP. Diagnosis, pathophysiology, and treatment of plantar verruca. Clin Podiatr Med Surg 1996;13:55-71.
21. Landow K. Nongenital warts: when is treatment, warranted? Postgrad Med 1996;99:245-9.
22. Robson KJ. Pulsed-dye laser versus conventional therapy in the treatment of warts: a prospective randomized trial. J Am Acad Dermatol 2000;43:275-80.
23. Silverberg NB. Squaric acid immunotherapy for warts in children. J Am Acad Dermatol 2000;42:803-8.
24. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143:1026-31.
25. Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. J Am Acad Dermatol 1996;34:1005-7.
26. Rogers CJ, Gibney MD, Siegfried EC, et al. Cimetidine therapy for recalcitrant warts in adults: is it any better than placebo? J Am Acad Dermatol 1999;41:123-7.
27. Karabulut AA, Sahin S, Eksioglu M. Is cimetidine effective for nongenital warts: a double-blind, placebo-controlled study [letter]. Arch Dermatol 1997;133:533-4.
28. Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999;40:93-5.
29. Lynch TJ. Duct tape removes warts. J Fam Pract 2003;52:111-2.
30. Harkness EF, Abbot NC, Ernst E. A randomized trial of distant healing for skin warts. Am J Med 2000;108:448-52.
31. Spanos NP, Williams V, Gwynn MI. Effects of hypnotic, placebo, and salicylic acid treatments on wart regression. Psychosom Med 1990;52:109-14.
32. Senkevich TG, Koonin EV, Bugert JJ, et al. The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. Virology 1997;233:19-42.
33. Smith KJ, Skelton H. Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. Am J Clin Dermatol 2002;3:535-45.
34. Braunwald E, Fauci A, Isselbacher KJ, et al. Harrison's online, Chapter 186. Columbus (OH): McGraw Hill.
35. Behrman RE. Nelson textbook of pediatrics. 16th edition. Orlando: W.B. Saunders; 2000. p. 2042.
36. Erythema multiforme-like molluscum dermatitis. Acta Derm Venereol 2002;82:217-8.
37. Smith KJ, Yeager J, Skelton H. Molluscum contagiosum: its clinical, histopathologic, and immunohistochemical spectrum. Int J Dermatol 1999;38:664-72.
38. Nico MM, Bergonse FN, Godoy AM. Molluscum contagiosum in herpes zoster scars. Int J Dermatol 2001;40:521-4.
39. Kaur S, Thami GP. Intraoral molluscum contagiosum. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontics 2002;94:279.
40. Ive FA. Follicular molluscum contagiosum. Br J Dermatol 1985;113:493-5.
41. Pfenninger JL, Fowler GC. Procedures for primary care.
42. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline for the management of molluscum contagiosum. Sex Transm Infect 1999;75(Suppl 1):S80-1.
43. Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol 2000;43:503-7.
44. Husar K, Skerlev M. Molluscum contagiosum from infancy to maturity. Clin Dermatol 2002;20:170-2.
45. Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998;25:309-13.
46. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of Molluscum contagiosum in children. Dermatol Online J 2001;7:20.
47. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55:1-13.
48. Kao CL, Lee CN, Lee WL, et al. Isolation and typing of herpes simplex virus from clinical specimens collected at National Taiwan University Hospital, 1981-1990. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1991;24:255-63.
49. Corey L. The current trend in genital herpes. Sex Transm Dis 1994-121(Suppl 2):S38-44.
50. Prober CG. Herpesvirus infections. In: Aly R, Maibach HI, editors. Atlas of infections of the skin NewYork: Churchill Livingstone; 1999. p. 185-94.
51. AAP 2000 Red Book: Report of the Committee on Infectious Diseases 25th edition. Elk Grove Village (IL): American Academy of Pediatrics; 2000.
52. Hairston B. Viral diseases of the oral mucosa. Dermatol Clin 2003;21:17-32.
53. Rapini RP, Jordan RE. Viral, rickettsial and chlamydial diseases. In: Rapini RP, Jordan RE, editors. Atlas of dermatopathology Chicago:Year Book Medical Publishers; 1988. p. 181-3.
54. Stevens A, Wheater PR, Lowe JS. Clinical dermatopathology: a text and color atlas. Edinburgh: Churchill Livingstone; 1989.
55. Vander Straten M, Carrasco D, Lee P, et al. A review of antiviral therapy for herpes labialis. Arch Dermatol 2001;137:1159-65.
56. Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections, I: characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976;41:498-507.
57. Rogers RS III, Mehregan DA. Disorders of the oral cavity. In: Moschella SL, Hurley HA, editors. Dermatology. 3rd edition. Philadelphia: W.B. Saunders; 1992. p. 2087-121.
58. Glezen WP, Fernald GW, Lohr JA. Acute respiratory disease of university students with special reference to the etiologic role of Herpesvirus hominis. Am J Epidemiol 1975;101:111-21.
59. Weathers DR, Griffin JW. Intraoral ulcerations of recurrent herpes simplex and recurrent aphthae: two distinct clinical entities. J Am Dent Assoc 1970;81:81-8.
60. Oranje AP, Folkers E, Choufoer-Habova J, et al. Diagnostic value of Tzanck smear in herpetic and non-herpetic vesicular and bullous skin disorders in pediatric practice. Acta Derm Venereol 1986;66:127-33.
61. Friedman E, Katcher AH, Brightman VJ. Incidence of recurrent herpes labialis and upper respiratory infection: a prospective study of the influence of biologic, social, and psychologic predictors. Oral Surg Oral Med Oral Pathol 1977;43:873-8.
62. Shipp II, Brightman VJ, Laster LL. The patient with recurrent aphthous ulcers and the patient with recurrent herpes labialis: a study of two population samples. J Am Dent Assoc 1967;75:645-54.
63. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993;118:268-72.
64. Shipp II, Miller MF, Ram C. A retrospective study of recurrent herpes labialis (RHL) in a professional population, 1958-1971. Oral Surg Oral Med Oral Pathol 1977;44:723-30.
65. Haynes RE, Azimi P, Cramblett H. Fatal herpes hominis (herpes simplex virus) infections in children: clinical, pathological, and virologic characteristics. JAMA 1968;206:312-9.
66. Spruance SL, Rea TL, Thoming C, et al. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 1997;277:1374-9.
67. Balfour HH Jr. Drug therapy: antiviral drugs. New Engl J Med 1999;340:1255-68.
68. Raborn GW, Martel AY, Grace MG, et al. Oral acyclovir in prevention of herpes labialis: a randomized, double-blind, multi-centered clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:55-9.
69. Evans TG, Bernstein DI, Raborn GW, et al. Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis. Antimicrob Agents Chemother 2002;46:1870-4.
70. Kaminester LH, Pariser RJ, Pariser DM, et al. A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis. J Am Acad Dermatol 1999; 41:996-1001.
71. Dougal G, Kelly P. A pilot study of treatment of herpes labialis with 1072 mn narrow waveband light. Clin Exp Dermatol 2001;26:149-54.
72. Johnson LW. Communal showers and the risk of plantar warts. J Fam Pract 1995;40:136-8.
73. McKeough MB, Spruance SL. Efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous Herpes Simplex Virus Type 1 infection. Arch Dermatol 2001;137:1153-8.
74. Sacks SL, Thisted RA, Jones TM, et al. The Docosanol 10% Cream Study Group. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001;45:222-30.
75. Saller R, Buechi S, Meyrat R, et al. Combined herbal preparation for topical treatment of Herpes labialis. Forsch Komplementarmed Klass Naturheilkd 2001;8:373-82.
76. Godfrey HR, Godfrey NJ, Godfrey JC, et al. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med 2001;7:49-56.
77. Glick M. Viral and fungal infections of the oral cavity in immunocompetent patients. Infect Dis Clin North Am 1999;13:817-31.
78. Kao CL, Lee CN, Lee WL, et al. Isolation and typing of herpes simplex virus from clinical specimens collected at National Taiwan University Hospital, 1981-1990. Zhonghua Min Goo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1991;24:255-63.
79. Delaney JE. Pediatric oral pathology: soft tissue and periodontal conditions. Pediatr Clin North Am 2000;47:1125-47.
80. Damjanov I, Linder J. Pathology: a color atlas. St.Louis: Mosby; 2000.
81. Amir J, Harel L, Smetana Z, et al. Treatment of herpes simplex gingivostomatitis with acyclovir in children: a randomised double blind placebo controlled study. BMJ 1997;314:1800-3.
82. Amir J. Primary herpetic gingivostomatitis: clinical aspects and anti-viral treatment. Harefuah 2002;141:81-4, 124.
83. Amir J. Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis. Paediatr Drugs 2001;3:593-7.
84. Cherry JD, Jahn CL. Herpangina: etiologic spectrum. Pediatrics 1965;36:632.
85. Morag A, Ogra PL. Enteroviruses. In: Behrman RE, editor. Nelson textbook of pediatrics 16th edition. Philadelphia: W.B. Saunders; 2000. p. 961-2.
86. Oxman MN. Enteroviruses. In: Cecil RL, Bennett JC, Goldman L, editors. Cecil textbook of medicine 21st edition. Philadelphia: W.B. Saunders; 2000. p. 1825-35.
87. Hebert AA, Lopez MD. Oral lesions in pediatric patients. Adv Dermatol 1997;12:169-93.
88. Ishimaru Y, Nakano S, Yamaoka K, et al. Outbreaks of hand, foot, and mouth disease by enterovirus 71: high incidence of complication disorders of central nervous system. Arch Dis Child 1980;55:583-8.
89. Treatment of plantar verrucae using 2% sodium salicylate iontophoresis. Phys Ther 2002; 82:1184-91.
90. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 2001; 137:1357-60.